Annotation

Biomedical research is already adjusting many traditional legal principles in civil, family, and inheritance law. Russian biomedical science is not inferior to world leaders in its success, presenting various achievements in the field of genomic editing, 3D bioprinting, and assisted reproductive technologies. At the same time, there is no proper legal support that would allow for the rapid and effective implementation of the obtained scientific results in Russian medical practice. In this regard, the article presents Singapore’s experience in regulating biomedical technologies. This city-state has achieved significant real success in developing the biomedical sector of the economy by creating legal, organizational, and infrastructural conditions and attracting a large amount of investment from leading research centers. The article discloses the main provisions of the Singapore Law of August 21, 2015, No. 29 “On Biomedical Research in Relation to Human Beings”. The lack of codification in this area is shown (the main regulatory acts in the field of biomedicine are highlighted), which is due to the peculiarities of the country’s legal system. The emphasis is placed on the regulatory functions of a special agency (A*STAR) responsible for the promotion of scientific research and monitoring of its implementation. Singapore provides clear guidance on bioethical principles, which are strictly monitored by various bodies, expert organizations and the professional medical community. Active support from the state ensures the participation of specialists from Singapore in all global public discussions, as well as the regular holding of international conferences, the outcome of which is the development of ethical recommendations. It is worth highlighting the Singapore Statement on Research Integrity, adopted at the Second World Conference on Research Integrity (22–24 July 2010).